Top

Published in:

Open Access 02-11-2023 | Respiratory Microbiota | Review

Helicobacter pylori and oral–gut microbiome: clinical implications

Authors: Maged T. Elghannam, Moataz H. Hassanien, Yosry A. Ameen, Emad A. Turky, Gamal M. ELattar, Ahmed A. ELRay, Mohammed D. ELTalkawy

Published in: Infection | Issue 2/2024

Abstract

More than half of the world’s population are colonized with H. pylori; however, the prevalence varies geographically with the highest incidence in Africa. H. pylori is probably a commensal organism that has been associated with the development of gastritis, ulcers, and gastric cancer. H. pylori alone is most probably not enough for the development of gastric carcinoma, but evidence for its association with the disease is high and has, therefore, been classified by the International Agency for Research on Cancer as a Class 1 carcinogen. Bacteroidetes and Fusobacteria positively coexisted during H. pylori infection along the oral–gut axis. The eradication therapy required to treat H. pylori infection can also have detrimental consequences for the gut microbiota, leading to a decreased alpha diversity. Therefore, therapy regimens integrated with probiotics may abolish the negative effects of antibiotic therapy on the gut microbiota. These eradication therapies combined with probiotics have also higher rates of eradication, when compared to standard treatments, and are associated with reduced side effects, improving the patient’s compliance. The eradication therapy not only affects gut microbiome but also affects the oral microbiome with robust predominance of harmful bacteria. However, there have been reports of a protective role of H. pylori in Barrett’s esophagus, esophageal adenocarcinoma, eosinophilic esophagitis, IBD, asthma, and even multiple sclerosis. Therefore, eradication therapy should be carefully considered, and test to treat policy should be tailored to specific communities especially in highly endemic areas. Supplementation of probiotics, prebiotics, herbals, and microbial metabolites to reduce the negative effects of eradication therapy should be considered. After failure of many eradication attempts, the benefits of H. pylori eradication should be carefully balanced against the risk of adverse effects especially in the elderly, persons with frailty, and intolerance to antibiotics.

Sitkin S, Lazebnik L, Avalueva E, Kononova S, Vakhitov T. Gastrointestinal microbiome and Helicobacter pylori: eradicate, leave it as it is, or take a personalized benefit–risk approach? World J Gastroenterol. 2022;28(7):766–74.CrossRefPubMedPubMedCentral

Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837–48. https://doi.org/10.1016/j.cell.2006.02.017.CrossRefPubMed

Azad M, Sarker M, Li T, Yin J. Probiotic species in the modulation of gut microbiota: an overview. Biomed Res Int. 2018. https://doi.org/10.1155/2018/9478630.CrossRefPubMedPubMedCentral

Malnick SD, Melzer E, Attali M, Duek G, Yahav J. Helicobacter pylori: friend or foe? World J Gastroenterol. 2014;20:8979–85. https://doi.org/10.3748/wjg.v20.i27.8979.CrossRefPubMedPubMedCentral

Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:4209.CrossRef

Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16:3–15.CrossRefPubMed

Hunt RH. The role of H. pylori in pathogenesis: the spectrum of clinical outcomes. Scand J Gastroenterol. 1996;31:3–9.CrossRef

Rothenbacher D, Brenner H. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect. 2003;5:693–703.CrossRefPubMed

Malaty HM. Epidemiology of Helicobacter pylori infection. Best Prac Res Clin Gastroenterol. 2007;21:205–14.CrossRef

10.

Kayali S, Manfredi M, Gaiani F, Bianchi L, Bizzarri B, Leandro G, et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Biomed. 2018;89:72–6. https://doi.org/10.23750/abm.v89i8-S.7947.CrossRefPubMed

11.

Sgambato D, Visciola G, Ferrante E, Miranda A, Romano L, Tuccillo C, et al. Prevalence of Helicobacter pylori infection in sexual partners of H. pylori-infected subjects: role of gastroesophageal reflux. United Eur Gastroenterol J. 2018;6:1470–6. https://doi.org/10.1177/2050640618800628.CrossRef

12.

Frenck RW Jr, Fathy HM, Sherif M, Mohran Z, El Mohammedy H, Francis W, et al. Sensitivity and specificity of various tests for the diagnosis of Helicobacter pylori in Egyptian children. Pediatrics. 2006;118:1195–202.CrossRef

13.

Waskito L, Rezkitha Y, Vilaichone R, Sugihartono T, Mustika S, Wibawa D, et al. The role of non-Helicobacter pylori bacteria in the pathogenesis of gastroduodenal diseases. Gut Pathogens. 2022;14:19. https://doi.org/10.1186/s13099-022-00494-0.CrossRefPubMedPubMedCentral

14.

Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biomed J. 2016;39:14–23. https://doi.org/10.1016/j.bj.2015.06.002.CrossRefPubMedPubMedCentral

15.

Goto Y, Uematsu S, Kiyono H. Epithelial glycosylation in gut homeostasis and inflammation. Nat Immunol. 2016;17:1244–51. https://doi.org/10.1038/ni.3587.CrossRefPubMed

16.

Chang WL, Yeh YC, Sheu BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci. 2018;25:68. https://doi.org/10.1186/s12929-018-0466-9.CrossRefPubMedPubMedCentral

17.

Ricci V, Giannouli M, Romano M, Zarrilli R. Helicobacter pylori gamma-glutamyl transpeptidase and its pathogenic role. World J Gastroenterol. 2014;20:630–8. https://doi.org/10.3748/wjg.v20.i3.630.CrossRefPubMedPubMedCentral

18.

Altobelli A, Bauer M, Velez K, Cover TL, Müller A. Helicobacter pylori VacA targets myeloid cells in the gastric lamina propria to promote peripherally induced regulatory T-cell differentiation and persistent infection. MBio. 2019. https://doi.org/10.1128/mBio.00261-19.CrossRefPubMedPubMedCentral

19.

D’Elios MM, Codolo G, Amedei A, Mazzi P, Berton G, Zanotti G, et al. Helicobacter pylori, asthma, and allergy. FEMS Immunol Med Microbiol. 2009;56:1–8. https://doi.org/10.1111/j.1574-695X.2009.00537.x.CrossRefPubMed

20.

Kienesberger S, Cox LM, Livanos A, Zhang XS, Chung J, Perez-Perez GI, et al. Gastric Helicobacter pylori infection affects local and distant microbial populations and host responses. Cell Rep. 2016;14:1395–407. https://doi.org/10.1016/j.celrep.2016.01.017.CrossRefPubMedPubMedCentral

21.

Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacter pylori infection in gastric carcinogenesis: current knowledge and future directions. World J Gastroenterol. 2015;21:11654–72. https://doi.org/10.3748/wjg.v21.i41.11654.CrossRefPubMedPubMedCentral

22.

Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet. 2002;359:14–22. https://doi.org/10.1016/S0140-6736(02)07273-2.CrossRefPubMed

23.

Papamichael K, Konstantopoulos P, Mantzaris GJ. Helicobacter pylori infection and inflammatory bowel disease: is there a link? World J Gastroenterol. 2014;20:6374–85. https://doi.org/10.3748/wjg.v20.i21.6374.CrossRefPubMedPubMedCentral

24.

Xiao M, Wang Y, Gao Y. Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis. PLoS ONE. 2013;8:e75559. https://doi.org/10.1371/journal.pone.0075559.CrossRefPubMedPubMedCentral

25.

Ertz-Archambault N, Keim P, Von Hoff D. Microbiome and pancreatic cancer: a comprehensive topic review of the literature. World J Gastroenterol. 2017;23:1899–908. https://doi.org/10.3748/wjg.v23.i10.1899.CrossRefPubMedPubMedCentral

26.

Wang ZW, Li Y, Huang LY, Guan QK, Xu DW, Zhou WK, et al. Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis. J Neurol. 2012;259:2527–37. https://doi.org/10.1007/s00415-012-6558-7.CrossRefPubMed

27.

Kountouras J, Boziki M, Zavos C, Gavalas E, Giartza-Taxidou E, Venizelos I, et al. A potential impact of chronic Helicobacter pylori infection on Alzheimer’s disease pathobiology and course. Neurobiol Aging. 2012;33:e3–4. https://doi.org/10.1016/j.neurobiolaging.2012.01.003.CrossRefPubMed

28.

Franceschi F, Covino M, Roubaud Baudron C. Review: Helicobacter pylori and extra-gastric diseases. Helicobacter. 2019;24:e12636. https://doi.org/10.1111/hel.12636.CrossRefPubMed

29.

Huang HK, Wang JH, Lei WY, Chen CL, Chang CY, Liou LS. Helicobacter pylori infection is associated with an increased risk of Parkinson’s disease: a population-based retrospective cohort study. Parkinsonism Relat Disord. 2018;47:26–31. https://doi.org/10.1016/j.parkreldis.2017.11.331.CrossRefPubMed

30.

Izadi M, Fazel M, Sharubandi SH, Saadat SH, Farahani MM, Nasseri MH, et al. Helicobacter species in the atherosclerotic plaques of patients with coronary artery disease. Cardiovasc Pathol. 2012;21:307–11. https://doi.org/10.1016/j.carpath.2011.09.011.CrossRefPubMed

31.

Park MJ, Choi SH, Kim D, Kang SJ, Chung SJ, Choi SY, et al. Association between Helicobacter pylori seropositivity and the coronary artery calcium score in a screening population. Gut Liver. 2011;5:321–7. https://doi.org/10.5009/gnl.2011.5.3.321.CrossRefPubMedPubMedCentral

32.

Jukic A, Bozic D, Kardum D, Becic T, Luksic B, Vrsalovic M, et al. Helicobacter pylori infection and severity of coronary atherosclerosis in patients with chronic coronary artery disease. Ther Clin Risk Manag. 2017;13:933–8. https://doi.org/10.2147/TCRM.S142193.CrossRefPubMedPubMedCentral

33.

Sharma V, Aggarwal A. Helicobacter pylori: does it add to the risk of coronary artery disease? World J Cardiol. 2015;7:19–25. https://doi.org/10.4330/wjc.v7.i1.19.CrossRefPubMedPubMedCentral

34.

Vijayvergiya R, Vadivelu R. Role of Helicobacter pylori infection in the pathogenesis of atherosclerosis. World J Cardiol. 2015;7:134–43. https://doi.org/10.4330/wjc.v7.i3.134.CrossRefPubMedPubMedCentral

35.

Santarelli L, Gabrielli M, Cremonini F, Santoliquido A, Candelli M, Nista EC, et al. Atrophic gastritis as a cause of hyperhomocysteinaemia. Aliment Pharmacol Ther. 2004;19:107–11. https://doi.org/10.1046/j.1365-2036.2003.01820.x.CrossRefPubMed

36.

Cárdenas VM, Boller F, Román GC. Helicobacter pylori, vascular risk factors and cognition in US older adults. Brain Sci. 2019;9:370. https://doi.org/10.3390/brainsci9120370.CrossRefPubMedPubMedCentral

37.

Yu M, Zhang R, Ni P, Chen S, Duan G. Helicobacter pylori infection and psoriasis: a systematic review and meta-analysis. Medicine (Kaunas). 2019. https://doi.org/10.3390/medicina55100645.CrossRef

38.

Onsun N, Arda Ulusal H, Su O, Beycan I, Biyik Ozkaya D, Senocak M. Impact of Helicobacter pylori infection on the severity of psoriasis and response to treatment. Eur J Dermatol. 2012;22:117–20. https://doi.org/10.1684/ejd.2011.1579.CrossRefPubMed

39.

Yorulmaz A, Kulcu SC. Helicobacter pylori and inflammatory skin diseases. World J Dermatol. 2015;4:120–8. https://doi.org/10.5314/wjd.v4.i3.120.CrossRef

40.

De Brito BB, Da Silva FAF, Soares AS, Pereira VA, Cordeiro Santos ML, Sampaio MM, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019;25:5578–89. https://doi.org/10.3748/wjg.v25.i37.5578.CrossRefPubMedPubMedCentral

41.

Kyburz A, Müller A. Helicobacter pylori and extragastric diseases. Curr Top Microbiol Immunol. 2017;400:325–47. https://doi.org/10.1007/978-3-319-50520-6_14.CrossRefPubMed

42.

Wu XW, Ji HZ, Yang MF, Wu L, Wang FY. Helicobacter pylori infection and inflammatory bowel disease in Asians: a meta-analysis. World J Gastroenterol. 2015;21:4750–6. https://doi.org/10.3748/wjg.v21.i15.4750.CrossRefPubMedPubMedCentral

43.

Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis. 2008;198:553–60. https://doi.org/10.1086/590158.CrossRefPubMed

44.

Miftahussurur M, Nusi IA, Graham DY, Yamaoka Y. Helicobacter, hygiene, atopy, and asthma. Front Microbiol. 2017;8:1034. https://doi.org/10.3389/fmicb.2017.01034.CrossRefPubMedPubMedCentral

45.

Tsigalou C, Konstantinidis TG, Cassimos D, Karvelas A, Grapsa A, Tsalkidis A, et al. Inverse association between Helicobacter pylori infection and childhood asthma in Greece: a case-control study. Germs. 2019;9:182–7. https://doi.org/10.18683/germs.2019.1174.CrossRefPubMedPubMedCentral

46.

Elias N, Nasrallah E, Khoury C, Mansour B, Abu Zuher L, Asato V, et al. Associations of Helicobacter pylori seropositivity and gastric inflammation with pediatric asthma. Pediatr Pulmonol. 2020;55:2236–45. https://doi.org/10.1002/ppul.24905.CrossRefPubMed

47.

Ierardi E, Losurdo G, Giorgio F, Di Leo A. Might Helicobacter pylori play a role in allergic or cross-reaction-related disorders? Expert Rev Gastroenterol Hepatol. 2020;14:643–6 (PMID: 32510247).CrossRefPubMed

48.

Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol. 1999;34:353–60. https://doi.org/10.1080/003655299750026353.CrossRefPubMed

49.

Shah S, Tepler A, Peek R, Colombel J, Hirano I, Narula N. Association between Helicobacter pylori exposure and decreased odds of eosinophilic esophagitis-a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(11):2185-2198.e3. https://doi.org/10.1016/j.cgh.2019.01.013.CrossRefPubMedPubMedCentral

50.

Rubenstein J, Inadomi J, Scheiman J, Schoenfeld P, Appelman H, Zhang M, et al. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol. 2014;12(2):239–45. https://doi.org/10.1016/j.cgh.2013.08.029.CrossRefPubMed

51.

Bor S, Kitapcioglu G, Kasap E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. World J Gastroenterol. 2017;23:525–32. https://doi.org/10.3748/wjg.v23.i3.525.CrossRefPubMedPubMedCentral

52.

Chen X, Wang N, Wang J, Liao B, Cheng L, Ren B. The interactions between oral gut axis microbiota and Helicobacter pylori. Front Cell Infect Microbiol. 2022;12: 914418. https://doi.org/10.3389/fcimb.2022.914418.CrossRefPubMedPubMedCentral

53.

Schulz C, Schütte K, Koch N, Vilchez-Vargas R, Wos-Oxley ML, Oxley APA, et al. The active bacterial assemblages of the upper GI tract in individuals with and without helicobacter infection. Gut. 2018;67:216–25. https://doi.org/10.1136/gutjnl-2016-312904.CrossRefPubMed

54.

Freitas D, Le Feunteun S, Panouille M, Souchon I. The important role of salivary a-amylase in the gastric digestion of wheat bread starch. Food Funct. 2018;9:200–8. https://doi.org/10.1039/C7FO01484H.CrossRefPubMed

55.

Wu ZF, Zou K, Xiang CJ, Jin ZJ, Ding HH, Xu S, et al. Helicobacter pylori infection is associated with the co-occurrence of bacteria in the oral cavity and the gastric mucosa. Helicobacter. 2021;26: e12786. https://doi.org/10.1111/hel.12786.CrossRefPubMed

56.

Chen X, Zhou X, Liao B, Zhou Y, Cheng L, Ren B. The cross-kingdom interaction between Helicobacter pylori and candida albicans. PloS Pathog. 2021;17: e1009515. https://doi.org/10.1371/journal.ppat.1009515.CrossRefPubMedPubMedCentral

57.

Park J, Shokeen B, Haake SK, Lux R. Characterization of fusobacterium nucleatum ATCC 23726 adhesins involved in strain-specific attachment to porphyromonas gingivalis. Int J Oral Sci. 2016;8:138–44. https://doi.org/10.1038/ijos.2016.27.CrossRefPubMedCentral

58.

Hathroubi S, Servetas SL, Windham I, Merrell DS, Ottemann KM. Helicobacter pylori biofilm formation and its potential role in pathogenesis. Microbiol Mol Biol Rev. 2018;82:e00001-e00018. https://doi.org/10.1128/MMBR.00001-18.CrossRefPubMedPubMedCentral

59.

Nomura R, Kadota T, Ogaya Y, Matayoshi S, Iwashita N, Okawa R, et al. Contribution of streptococcus mutans to Helicobacter pylori colonization in the oral cavity and gastric tissue. Sci Rep. 2020;10:12540. https://doi.org/10.1038/s41598-020-69368-2.CrossRefPubMedPubMedCentral

60.

Palencia SL, Garcıa A, Palencia M. Multiple surface interaction mechanisms direct the anchoring, co-aggregation and formation of dual-species biofilm between candida albicans, and Helicobacter pylori. J Adv Res. 2022;35:169–85. https://doi.org/10.1016/j.jare.2021.03.013.CrossRefPubMed

61.

Saniee P, Siavoshi F, Nikbakht Broujeni G, Khormali M, Sarrafnejad A, Malekzadeh R. Localization of H. pylori within the vacuole of candida yeast by direct immunofluorescence technique. Arch Iranian Med. 2013;16:705–10.

62.

Miller DP, Scott DA. Inherently and conditionally essential protein catabolism genes of p. gingivalis. Trends Microbiol. 2021;29:54–64. https://doi.org/10.1016/j.tim.2020.09.002.CrossRefPubMed

63.

Park SY, Hwang BO, Lim M, Ok SH, Lee SK, Chun KS, et al. Oral-gut microbiome axis in gastrointestinal disease and cancer. Cancers (Basel). 2021;13:2124. https://doi.org/10.3390/cancers13092124.CrossRefPubMed

64.

Monstein HJ, Tiveljung A, Kraft CH, Borch K, Jonasson J. Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori-associated gastritis and histologically normal control individuals by temperature gradient gel electrophoresis and 16S rDNA sequence analysis. J Med Microbiol. 2000;49:817–22.CrossRefPubMed

65.

Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA. 2006;103:732–7.CrossRefPubMedPubMedCentral

66.

Zoetendal G, Raes J, van den Bogert B, Arumugam M, Booijink M, Troost J, et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME J. 2012;6:1415–26. https://doi.org/10.1038/ismej.2011.212.CrossRefPubMedPubMedCentral

67.

Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–6. https://doi.org/10.1038/nature12506.CrossRefPubMed

68.

Coker O, Dai W, Nie Z, Zhao J, Cao L, Nakatsu G, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67:1024–32. https://doi.org/10.1136/gutjnl-2017-314281.CrossRefPubMed

69.

Liu D, Chen S, Gou Y, Yu W, Zhou H, Zhang R, et al. Gastrointestinal microbiota changes in patients with gastric precancerous lesions. Front Cell Microbiol. 2021. https://doi.org/10.3389/fcimb.2021.749207.CrossRef

70.

Nardone G, Compare D, Rocco A. A microbiota-centric view of diseases of the upper gastrointestinal tract. Lancet Gastroenterol Hepatol. 2017;2:298–312.CrossRefPubMed

71.

Hojo M, Asahara T, Nagahara A, Takeda T, Matsumoto K, Ueyama H, et al. Gut microbiota composition before and after use of proton pump inhibitors. Dig Dis Sci. 2018;63:2940–9.CrossRefPubMedPubMedCentral

72.

Gao J, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, et al. Association between gut microbiota and Helicobacter pylori-related gastric lesions in a high-risk population of gastric cancer. Front Cell Infect Microbiol. 2018;8:202.CrossRefPubMedPubMedCentral

73.

Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, Karaoz U, Contreras M, Blaser MJ, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 2011;5:574–9. https://doi.org/10.1038/ismej.2010.149.CrossRefPubMed

74.

Lopetuso LR, Napoli M, Rizzatti G, Scaldaferri F, Franceschi F, Gasbarrini A. Considering gut microbiota disturbance in the management of Helicobacter Pylori infection. Expert Rev Gastroenterol Hepatol. 2018;12:899–906. https://doi.org/10.1080/17474124.2018.1503946.CrossRefPubMed

75.

Dash NR, Khoder G, Nada AM, Al Bataineh MT. Exploring the impact of Helicobacter pylori on gut microbiome composition. PLoS ONE. 2019;14: e0218274. https://doi.org/10.1371/journal.pone.0218274PONE-D-19-03006.CrossRefPubMedPubMedCentral

76.

Frost F, Kacprowski T, Rühlemann M, Bang C, Franke A, Zimmermann K, et al. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Sci Rep. 2019;9:20100. https://doi.org/10.1038/s41598-019-56631-4.CrossRefPubMedPubMedCentral

77.

He C, Peng C, Wang H, Ouyang Y, Zhu Z, Shu X, et al. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. Helicobacter. 2019;24: e12590. https://doi.org/10.1111/hel.12590.CrossRefPubMed

78.

Benavides-Ward A, Vasquez-Achaya F, Silva-Caso W, Aguilar-Luis MA, Mazulis F, Urteaga N, et al. Helicobacter pylori and its relationship with variations of gut microbiota in asymptomatic children between 6 and 12 years. BMC Res Notes. 2018;11:468. https://doi.org/10.1186/s13104-018-3565-5.CrossRefPubMedPubMedCentral

79.

Iino C, Shimoyama T, Chinda D, Arai T, Chiba D, Nakaji S, et al. Infection of Helicobacter pylori and atrophic gastritis influence lactobacillus in gut microbiota in a Japanese population. Front Immunol. 2018;9:712. https://doi.org/10.3389/fimmu.2018.00712.CrossRefPubMedPubMedCentral

80.

Xiao S, Zhao L. Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation. FEMS Microbiol Ecol. 2014;87:303–14. https://doi.org/10.1111/1574-6941.12250.CrossRefPubMed

81.

Chen L, Xu W, Lee A, He J, Huang B, Zheng W, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBio Med. 2018;35:87–96. https://doi.org/10.1016/j.ebiom.2018.08.028.CrossRef

82.

Fiorani M, Tohumcu E, Del Vecchio LE, Porcari S, Cammarota G, Gasbarrini A, Ianiro G. The influence of Helicobacter pylori on human gastric and gut microbiota. Antibiotics. 2023;12:765. https://doi.org/10.3390/antibiotics12040765.CrossRefPubMedPubMedCentral

83.

Dewayani A, Afrida Fauzia K, Alfaray RI, Waskito LA, Doohan D, Rejeki PS, et al. Gastric microbiome changes in relation with Helicobacter pylori resistance. PLoS ONE. 2023;18: e0284958. https://doi.org/10.1371/journal.pone.0284958.CrossRefPubMedPubMedCentral

84.

Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014;124:4212–8. https://doi.org/10.1172/JCI72333.CrossRefPubMedPubMedCentral

85.

Reijnders D, Goossens GH, Hermes GDA, Neis EPJG, van der Beek CM, Most J, et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab. 2016;24:63–74. https://doi.org/10.1016/j.cmet.2016.06.016.CrossRefPubMed

86.

Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS ONE. 2010;5:e9836. https://doi.org/10.1371/journal.pone.0009836.CrossRefPubMedPubMedCentral

87.

Gotoda T, Takano C, Kusano C, Suzuki S, Ikehara H, Hayakawa S, et al. Gut microbiome can be restored without adverse events after Helicobacter pylori eradication therapy in teenagers. Helicobacter. 2018;23: e12541.CrossRefPubMed

88.

Wu L, Wang Z, Sun G, Peng L, Lu Z, Yan B, et al. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep. 2019;9:12874. https://doi.org/10.1038/s41598-019-49415-310.1038/s41598-019-49415-3.CrossRefPubMedPubMedCentral

89.

Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicenter, open-label, randomized trial. Lancet Infect Dis. 2019;19:1109–20. https://doi.org/10.1016/S1473-3099(19)30272-5.CrossRefPubMed

90.

Martın-Núñez GM, Cornejo-Pareja I, Coin-Aragüez L, Roca-Rodrıguez MDM, Muñoz-Garach A, Clemente-Postigo M, et al. Pylori eradication with antibiotic treatment causes changes in glucose homeostasis related to modifications in the gut microbiota. PLoS ONE. 2019;14:e0213548. https://doi.org/10.1371/journal.pone.0213548.CrossRefPubMedPubMedCentral

91.

Kakiuchi T, Mizoe A, Yamamoto K, Imamura I, Hashiguchi K, Kawakubo H, et al. Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: a randomized controlled Trial. Helicobacter. 2020;25: e12690. https://doi.org/10.1111/hel.12690.CrossRefPubMed

92.

Hsu P-II, Pan C-YY, Kao JY, Tsay F-WW, Peng N-JJ, Kao S-SS, et al. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of proteobacteria and decreased relative abundances of bacteroidetes and actinobacteria. Helicobacter. 2018;10:e12498. https://doi.org/10.1111/hel.12498.CrossRef

93.

Tang B, Tang L, Huang C, Tian C, Chen L, He Z, et al. The Effect of probiotics supplementation on gut microbiota after Helicobacter pylori eradication: a multicenter randomized controlled trial. Infect Dis Ther. 2021;10:317–33. https://doi.org/10.1007/s40121-020-00372-910.1007/s40121-020-00372-9.CrossRefPubMed

94.

Niu ZY, Li SZ, Shi YY, Xue Y. Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth. World J Gastroenterol. 2021;27(25):3913–24.CrossRefPubMedPubMedCentral

95.

Tawfik SA, Azab M, Ramadan M, Shabayek S, Abdellah A, Al Thagfan SS, Salah M. The eradication of Helicobacter pylori was significantly associated with compositional patterns of orointestinal axis microbiota. Pathogens. 2023;12:832. https://doi.org/10.3390/pathogens12060832.CrossRefPubMedPubMedCentral

96.

Li J, Perez-Perez GI. Helicobacter pylori the latent human pathogen or an ancestral commensal organism. Front Microbiol. 2018;9:609. https://doi.org/10.3389/fmicb.2018.00609.CrossRefPubMedPubMedCentral

97.

Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449–61. https://doi.org/10.1016/S0140-6736(09)60938-7.CrossRefPubMed

98.

Stein M, Ruggiero P, Rappuoli R, Bagnoli F. Helicobacter pylori CagA: from pathogenic mechanisms to its use as an anti-cancer vaccine. Front Immunol. 2013;4:328. https://doi.org/10.3389/fimmu.2013.00328.CrossRefPubMedPubMedCentral

99.

Calvet X, Ramírez Lázaro MJ, Lehours P, Mégraud F. Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter. 2013;18:5–11. https://doi.org/10.1111/hel.12071.CrossRefPubMed

100.

Walker MM, Talley NJ. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract–beyond the era of Helicobacter pylori. Aliment Pharmacol Ther. 2014;39:767–79. https://doi.org/10.1111/apt.12666.CrossRefPubMed

101.

Tsimmerman YS. Critical analysis of the Helicobacter pylori-infection leading role in the development of gastroduodenal diseases. Clin Pharmacol Ther. 2019;28:19–27.CrossRef

102.

Shiota S, Thrift AP, Green L, Shah R, Verstovsek G, Rugge M, Graham DY, El-Serag HB. Clinical manifestations of Helicobacter pylori-negative gastritis. Clin Gastroenterol Hepatol. 2017;15:1037-46.e3.CrossRefPubMed

103.

Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Wibawa ID, Rezkitha YA, Siregar G, Yulizal OK, Akil F, Uwan WB, Simanjuntak D. Analysis of risks of gastric cancer by gastric mucosa among Indonesian ethnic groups. PLoS ONE. 2019;14: e0216670.CrossRefPubMedPubMedCentral

104.

Pereira-Marques J, Ferreira RM, Pinto-Ribeiro I, Figueiredo C. Helicobacter pylori infection, the gastric microbiome and gastric cancer. Adv Exp Med Biol. 2019;1149:195–210.CrossRefPubMed

105.

Nordenstedt H, Graham DY, Kramer JR, Rugge M, Verstovsek G, Fitzgerald S, Alsarraj A, Shaib Y, Velez ME, Abraham N, Anand B, Cole R, El-Serag HB. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013;108:65–71.CrossRefPubMed

106.

Araújo MB, Borini P, Guimarães RC. Etiopathogenesis of peptic ulcer: back to the past? Arq Gastroenterol. 2014;51:155–61. https://doi.org/10.1590/s0004-28032014000200016.CrossRefPubMed

107.

Figura N, Guglielmetti P, Rossolini A, Barberi A, Cusi G, Musmanno RA, Russi M, Quaranta S. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol. 1989;27:225–6. https://doi.org/10.1128/JCM.27.1.225-226.1989.CrossRefPubMedPubMedCentral

108.

Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem. 1995;270:17771–7. https://doi.org/10.1074/jbc.270.30.17771.CrossRefPubMed

109.

Diab M, Shemis M, Gamal D, El-Shenawy A, El-Ghannam M, El-Sherbini E, et al. Helicobacter pylori western cagA genotype in Egyptian patients with upper gastrointestinal disease. Egypt J Med Human Genetics. 2018;19:297–300.CrossRef

110.

El-Shenawy A, Diab M, Shemis M, ElGhannam M, Salem D, Abdelnasser M, et al. Detection of Helicobacter pylori vacA, cagA and iceA1 virulence genes associated with gastric diseases in Egyptian patients. Egypt J Medi Human Genetics. 2017;18(4):365–71.CrossRef

111.

Khosravi Y, Dieye Y, Poh BH, Ng CG, Loke MF, Goh KL, et al. Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients. Sci World J. 2014;2014: 610421. https://doi.org/10.1155/2014/610421.CrossRef

112.

Iijima K, Kanno T, Abe Y, Yagi M, Asonuma S, Ohyauchi M, et al. Preferential location of idiopathic peptic ulcers. Scand J Gastroenterol. 2016;51(7):782–7. https://doi.org/10.3109/00365521.2016.1141316.CrossRefPubMed

113.

Kanno T, Iijima K, Abe Y, Yagi M, Asonuma S, Ohyauchi M, Ito H, Koike T, Shimosegawa T. Helicobacter pylori-negative and non-steroidal anti-inflammatory drugs-negative idiopathic peptic ulcers show refractoriness and high recurrence incidence: multicenter follow-up study of peptic ulcers in Japan. Dig Endosc. 2016;28:556–63. https://doi.org/10.1111/den.12635.CrossRefPubMed

114.

Rasane RK, Horn CB, Coleoglou Centeno AA, Fiore NB, Torres Barboza M, Zhang Q, Bochicchio KM, Punch LJ, Bochicchio GV, Ilahi ON. Are patients with perforated peptic ulcers who are negative for Helicobacter pylori at a greater risk? Surg Infect (Larchmt). 2019;20:444–8. https://doi.org/10.1089/sur.2018.249.CrossRefPubMed

115.

Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? Am J Gastroenterol. 1998;93:1409–15. https://doi.org/10.1111/j.1572-0241.1998.452_a.x.CrossRefPubMed

116.

Tsimmerman YS. Gastric cancers: a modern approach to the problem. Vestnik chirurgicheskoj gastroenterologii. 2011;2:77–88.

117.

Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949–58. https://doi.org/10.1046/j.1365-2036.2001.01109.x.CrossRefPubMed

118.

Lamb A, Chen LF. Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. J Cell Biochem. 2013;114:491–7. https://doi.org/10.1002/jcb.24389.CrossRefPubMedPubMedCentral

119.

Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.PubMed

120.

Rokkas F. Helicobacter pylori infection as risk factor of carcinoma of the stomach: current evidence. Russ J Gastroenterol Hepatol Coloproctol. 2002;3:66–70.

121.

Yu G, Gail H, Shi J, Klepac-Ceraj V, Paster J, Dye A, et al. Association between upper digestive tract microbiota and cancer-predisposing states in the esophagus and stomach. Cancer Epidemiol Biomarkers Prev. 2014;23:735–41. https://doi.org/10.1158/1055-9965.EPI-13-0855.CrossRefPubMedPubMedCentral

122.

El Maznya A, Hishmata T, Husseina A, Gaithb D. The prevalence of Helicobacter pylori cagA (+ve) among patients with gastric cancer: an Egyptian study. Egypt J Intern Med. 2019;31:522–8.CrossRef

123.

Venerito M, Vasapolli R, Rokkas T, Malfertheiner P. Gastric cancer: epidemiology, prevention, and therapy. Helicobacter. 2018;23:e12518. https://doi.org/10.1111/hel.12518.CrossRefPubMed

124.

Merchant SJ, Kim J, Choi AH, Sun V, Chao J, Nelson R. A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer. 2017;20:226–34. https://doi.org/10.1007/s10120-016-0603-7.CrossRefPubMed

125.

Miftahussurur M, Yamaoka Y, Graham DY. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med. 2017;19: e4.CrossRefPubMedPubMedCentral

126.

Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, MacHado JC, Figueiredo C. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67:226–36.CrossRefPubMed

127.

Camargo MC, Anderson WF, King JB, Correa P, Thomas CC, Rosenberg PS, Eheman CR, Rabkin CS. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 2011;60:1644–9. https://doi.org/10.1136/gut.2010.236737.CrossRefPubMed

128.

Mentis A, Boziki M, Grigoriadis N, Papavassiliou A. Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cel Mol Life Sci. 2019;76:2477–86. https://doi.org/10.1007/s00018-019-03044-1.CrossRef

129.

Ralser A, Dietl A, Jarosch S, et al. Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature. Gut. 2023;72:1258–70.CrossRefPubMed

130.

Peng L, Guo Y, Gerhard M, Gao J, Liu Z, Mejías-Luque R, et al. Metabolite alterations and interactions with microbiota in Helicobacter pylori-associated gastric lesions. Micobiol Spectr. 2023;11:e05347-e5422. https://doi.org/10.1128/spectrum.05347-22.CrossRef

131.

Arai J, Niikura R, Hayakawa Y, et al. Use of antibiotics and probiotics reduces the risk of metachronous gastric cancer after endoscopic resection. Biology (Basel). 2021;10:455.PubMed

132.

Niikura R, Hayakawa Y, Nagata N, Miyoshi-Akiayama T, Miyabayashi K, Tsuboi M, et al. Non-Helicobacter pylori gastric microbiome modulates prooncogenic responses and is associated with gastric cancer risk. Gastro Hep Adv. 2023;2:684–700.CrossRef

133.

Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7:CD005583. https://doi.org/10.1002/14651858.CD005583.pub3.CrossRefPubMed

134.

He C, Peng C, Xu X, Li N, Ouyang Y, Zhu Y, et al. Probiotics mitigate Helicobacter pylori-induced gastric inflammation and premalignant lesions in INSGAS mice with the modulation of gastrointestinal microbiota. Helicobacter. 2022;27: e12898. https://doi.org/10.1111/hel.12898.CrossRefPubMed

135.

Viazis N, Argyriou K, Kotzampassi K, Christodoulou D, Apostolopoulos P, Georgopoulos S, et al. A four-probiotics regimen combined with a standard Helicobacter pylori-eradication treatment reduces side effects and increases eradication rates. Nutrients. 2022;14:632. https://doi.org/10.3390/nu14030632.CrossRefPubMedPubMedCentral

136.

Baryshnikova NV, Ilina AS, Ermolenko EI, Uspenskiy YP, Suvorov AN. Probiotics and autoprobiotics for treatment of Helicobacter pylori infection. World J Clin Cases. 2023;11(20):4740–51. https://doi.org/10.12998/wjcc.v11.i20.4740.CrossRefPubMedPubMedCentral

137.

Yuan Z, Xiao S, Li S, Suo B, Wang Y, Meng L, et al. The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter. 2021;26: e12848. https://doi.org/10.1111/hel.12848.CrossRefPubMed

138.

Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol. 2021;2021(21):388. https://doi.org/10.1186/s12876-021-01977-1.CrossRef

139.

Zhang L, Zhao M, Fu X. Gastric microbiota dysbiosis and Helicobacter pylori infection. Front Microbiol. 2023;14:1153269. https://doi.org/10.3389/fmicb.2023.1153269.CrossRefPubMedPubMedCentral

140.

Yang C, Liang L, Lv P, Liu L, Wang S, Wang Z, Chen Y. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: a randomized double-blind placebo-controlled trial. Helicobacter. 2021;26: e12856. https://doi.org/10.1111/hel.12856.CrossRefPubMed

141.

Kamiya S, Yonezawa H, Osaki T. Role of probiotics in eradication therapy for Helicobacter pylori infection. Adv Exp Med Biol. 2019;1149:243–55.CrossRefPubMed

142.

Quin C, Estaki M, Vollman DM, Barnett JA, Gill SK, Gibson DL. Probiotic supplementation and associated infant gut microbiome and health: a cautionary retrospective clinical comparison. Sci Rep. 2018;8:8283. https://doi.org/10.1038/s41598-018-26423-3.CrossRefPubMedPubMedCentral

143.

Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, Zur M, Regev- Lehavi D, Ben-Zeev Brik R, Federici S, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174:1406-1423.e1416. https://doi.org/10.1016/j.cell.2018.08.047.CrossRefPubMed

144.

Murros KE, Huynh VA, Takala TM, Saris PEJ. Desulfovibrio bacteria are associated with Parkinson’s disease. Front Cell Infect Microbiol. 2021;11: 652617. https://doi.org/10.3389/fcimb.2021.652617.CrossRefPubMedPubMedCentral

145.

Guillemard E, Poirel M, Schäfer F, Quinquis L, Rossoni C, Keicher C, Wagner F, Szajewska H, Barbut F, Derrien M, et al. A randomized, controlled trial: effect of a multi-strain fermented milk on the gut microbiota recovery after Helicobacter pylori therapy. Nutrients. 2021;13(9):3171. https://doi.org/10.3390/nu13093171.CrossRefPubMedPubMedCentral

146.

Nabavi-Rad A, Sadeghi A, Yadegar A, Smith S, Zali M. The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management. Gut Microbes. 2022;14:e2108655. https://doi.org/10.1080/19490976.2022.2108655.CrossRef

147.

Ye Z, Xia H, Zhang R, Li L, Wu L, Liu X, et al. The efficacy of washed microbiota transplantation on Helicobacter pylori eradication: a pilot study. Gastroenterol Res Pract. 2020;2020:8825189. https://doi.org/10.1155/2020/8825189.CrossRefPubMedPubMedCentral

148.

Grosen A, Mikkelsen S, Baunwall S, Dahlerup J, Erikstrup L, Hvas C, et al. Risk of Helicobacter pylori transmission by faecal microbiota transplantation via oral capsules. Clin Microbiol Infect. 2023;29:799e1–4.CrossRef

149.

Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160:1831–41. https://doi.org/10.1053/j.gastro.2020.11.059.CrossRefPubMed

Title: Helicobacter pylori and oral–gut microbiome: clinical implications
Authors: Maged T. Elghannam
Moataz H. Hassanien
Yosry A. Ameen
Emad A. Turky
Gamal M. ELattar
Ahmed A. ELRay
Mohammed D. ELTalkawy
Publication date: 02-11-2023
Publisher: Springer Berlin Heidelberg
Keywords: Respiratory Microbiota
Gastric Cancer
Gastric Cancer
Gastritis
Helicobacter Pylori
Probiotics
Published in: Infection / Issue 2/2024
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-023-02115-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Rate and predictors of blood culture positivity after antibiotic administration: a prospective single-center study

Assessing the current epidemiological status of SARS-CoV-2 and its potential evolution

Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India

Blood T cell phenotypes correlate with fatigue severity in post-acute sequelae of COVID-19

Clinical and epidemiological factors causing longer SARS-CoV 2 viral shedding: the results from the CoviCamp cohort

Cerebral phaeohyphomycosis due to Cladophialophora bantiana: case report and systematic review of cases

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials